ArticleBMC infectious diseases2026
Albumin-corrected anion gap and 28-/90-day mortality in cirrhotic patients with invasive fungal infection: a retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic role of the albumin-corrected anion gap (ACAG) in cirrhotic patients with invasive fungal infection (IFI) remains unclear. This retrospective cohort study aimed to investigate the association between ACAG and 28-/90-day mortality in this high-risk population.
methodsA retrospective cohort study was conducted at Beijing Ditan Hospital, including patients with cirrhosis complicated by IFI who were admitted between January 2009 and December 2021. ACAG was calculated using initial anion gap and albumin measurements within 24 h of admission. Patients were stratified into high and normal ACAG groups by an ACAG cutoff of 20 mmol/L. The primary outcomes were 28-day and 90-day all-cause mortality. Cox proportional hazards regression models and Kaplan-Meier survival analysis were employed to assess the association between ACAG levels and mortality outcomes. Subgroup analyses were performed to explore the consistency of the association. The prognostic value of ACAG was assessed by receiver operating characteristic (ROC) curve analysis.
resultsA total of 313 cirrhotic patients with IFI were enrolled. Patients with high ACAG (≥ 20 mmol/L) had significantly higher 28-day (36.44% vs. 12.82%, P < 0.001) and 90-day mortality (55.93% vs. 25.13%, P < 0.001) compared to the normal ACAG group. After adjusting covariates (Model3), elevated ACAG levels remained an independent risk factor for both 28-day (adjusted HR = 1.06, 95% CI: 1.01-1.11, P = 0.03) and 90-day mortality (adjusted HR = 1.05, 95% CI: 1.01-1.1, P = 0.018). When ACAG was analyzed as a categorical variable, the high ACAG group exhibited a significantly higher mortality rate compared with the normal ACAG group. The results remained consistent across all subgroups. The ACAG demonstrated good predictive ability, with an AUC of 0.721 (95% CI: 0.653-0.790) for 28-day mortality. The AUC value of ACAG for predicting 90-day mortality was 0.699. Furthermore, the predictive performance for both 28-day and 90-day mortality was improved by combining ACAG with the MELD score, yielding AUCs of 0.803 (95% CI: 0.741-0.865) and 0.750 (95% CI: 0.693-0.807), respectively.
conclusionACAG was an independent predictor of 28-/90-day mortality in cirrhotic patients with IFI, and may serve as a valuable and readily available prognostic biomarker to complement existing risk assessment tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.